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Abstract
Background: Initiation and regulation of immune responses in humans involves recognition of
peptides presented by human leukocyte antigen class II (HLA-II) molecules. These peptides (HLA-
II T-cell epitopes) are increasingly important as research targets for the development of vaccines
and immunotherapies. HLA-II peptide binding studies involve multiple overlapping peptides
spanning individual antigens, as well as complete viral proteomes. Antigen variation in pathogens
and tumor antigens, and extensive polymorphism of HLA molecules increase the number of targets
for screening studies. Experimental screening methods are expensive and time consuming and
reagents are not readily available for many of the HLA class II molecules. Computational prediction
methods complement experimental studies, minimize the number of validation experiments, and
significantly speed up the epitope mapping process. We collected test data from four independent
studies that involved 721 peptide binding assays. Full overlapping studies of four antigens identified
binding affinity of 103 peptides to seven common HLA-DR molecules (DRB1*0101, 0301, 0401,
0701, 1101, 1301, and 1501). We used these data to analyze performance of 21 HLA-II binding
prediction servers accessible through the WWW.
Results: Because not all servers have predictors for all tested HLA-II molecules, we assessed a
total of 113 predictors. The length of test peptides ranged from 15 to 19 amino acids. We tried
three prediction strategies – the best 9-mer within the longer peptide, the average of best three 9-
mer predictions, and the average of all 9-mer predictions within the longer peptide. The best
strategy was the identification of a single best 9-mer within the longer peptide. Overall, measured
by the receiver operating characteristic method (AROC), 17 predictors showed good (AROC > 0.8),
41 showed marginal (AROC > 0.7), and 55 showed poor performance (AROC < 0.7). Good
performance predictors included HLA-DRB1*0101 (seven), 1101 (six), 0401 (three), and 0701
(one). The best individual predictor was NETMHCIIPAN, closely followed by PROPRED, IEDB
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for prediction of promiscuous peptides. Current predictive capabilities allow prediction of only
50% of actual T-cell epitopes using practical thresholds.
Conclusion: The available HLA-II servers do not match prediction capabilities of HLA-I
predictors. Currently available HLA-II prediction servers offer only a limited prediction accuracy
and the development of improved predictors is needed for large-scale studies, such as proteome-
wide epitope mapping. The requirements for accuracy of HLA-II binding predictions are stringent
because of the substantial effect of false positives.
Introduction
Vaccines are the most effective means for fighting against
infectious diseases [1]. They are emerging as promising
therapies for cancer [2], allergy [3], and autoimmunity
[4]. The goal of vaccination is to induce immunity against
pathogens and cancer cells by stimulating antigen-specific
cytotoxic T lymphocytes (CTLs) or B cells. CTLs recognize
peptide antigens presented by major histocompatibility
complex class I (MHC-I) molecules on infected cells or
cancer cells and kill them. B cells produce antibodies that
specifically recognize pathogen- or cancer related mole-
cules. Both these processes are initiated and regulated by
T-helper (Th) cells that recognize antigenic peptides pre-
sented by MHC class II (MHC-II) molecules. MHC-II mol-
ecules present antigenic peptides internalized by
professional antigen presenting cells, such as macro-
phages, dendritic cells, or T lymphocytes. A vaccine must
at minimum contain two antigenic epitopes: one to
induce specific B-cell or CTL responses and another to
induce specific Th cells that regulate (initiate, enhance, or
suppress) immune responses [5]. Peptides presented by
MHC-I molecules are mainly intracellular and those pre-
sented by MHC-II molecules originate mainly from or
extracellular proteins. A distinct characteristic of MHC
molecules of either class is a groove that binds peptides in
a highly promiscuous manner.
The peptide-binding groove of a MHC molecule consists
of a β-sheet and two α-helices. A peptide binds through a
network of hydrogen bonds between its backbone and the
binding groove, and through interactions between the
peptide side chains and pockets inside the binding groove
[6,7]. Most MHC-I binding peptides are 8–11 amino acids
long [8]. MHC-II molecules bind nested sets of peptides
most of which are 14–18 amino acids long [9], but some
can extend beyond 30 amino acids. MHC-I molecules
accommodate the whole length of the binding peptide
inside their grooves that are closed [6]. Binding grooves of
a MHC-II molecules have open ends; they accommodate
the 9-mer binding core of the peptides inside while pep-
tide termini protrude outside of the grooves [7].
The ability of the immune system to respond to a particu-
lar antigen differs between individuals because they dis-
play different patterns of MHC genes. Human MHC
molecules are known as human leukocyte antigens. Each
human individual expresses up to six HLA-I molecules
and up to a dozen HLA-II molecules. HLA genes show
extensive polymorphism. As of August 2008, more than
3000 HLA alleles have been identified and sequenced
including 2215 HLA-I and 986 HLA-II sequences [10]. The
diversity of HLA molecules increases the probability that
any foreign antigen will contain HLA-binding peptides
suitable as vaccine targets. The amino acids within the
binding groove determine the specificity of peptide bind-
ing to a given HLA molecule. Across multiple HLA mole-
cules, the polymorphic residues that form the binding
groove determine the repertoire of binding peptides to a
particular HLA molecule. Tens of thousands of allele-spe-
cific and promiscuous MHC binders and T-cell epitopes
have been identified in humans and mice while smaller
numbers have been identified in other model animals,
such as monkeys and rats [11,12].
Identification of HLA binding molecules is, therefore,
important for both understanding the basing molecular
function of the immune system and for vaccine develop-
ment. However, systematic T-cell epitope mapping is
costly and time-consuming because it involves synthesis
and testing of overlapping peptides spanning the full
length of target antigens. For short peptides such as tumor
antigen surviving (BIRC5), that is 142 amino acids long,
full overlapping studies of both HLA-I and -II binders
were performed for several HLA molecules [13,14]. How-
ever systematic studies are prohibitively expensive for
studies of long antigens, such as autoantigen thyroglobu-
lin (2768 amino acids long), where computational pre-
dictions were used to preselect suitable targets followed by
experimental validation [15,16]. This problem is particu-
larly pronounced in the studies of whole pathogen pro-
teomes, even in small viruses, such as influenza [17], or
dengue [18].
Computational prediction of peptide binding to MHC
molecules has been a topic of vigorous research and devel-
opment activity [19-22]. Computational methods for pre-
diction of HLA-I binding have reached a high level of
sophistication and accuracy and represent significantPage 2 of 10
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HLA-II binding were useful in the study of infectious dis-
ease [24,25], cancer [26,27], and autoimmunity [15,16].
However, recent reports have indicated that computa-
tional predictions of HLA-II binding are of much lower
accuracy than for their HLA-I counterparts [28,29], and
even that these predictions may cause more confusion
than conclusion [30]. The methods used for assessment of
predictors of HLA-II binding have suffered from inade-
quately defined test sets and testing strategies. Several crit-
ical issues need to be addressed to rectify these failings.
• Only a small fraction of peptides in a given pathogen or
tumor-specific proteome are able to bind to a specific
MHC molecule [31]. Tens of thousands of protein vari-
ants have been characterized in viruses [17,18]. Several
hundred of tumor-related antigens and their variants have
been reported [32,33]. The extensive variability of target
antigens significantly increases the number of testable tar-
gets, making each individual binding peptide a represent-
ative of a large family of individual peptide groups or
families [34].
• The comparison studies performed to date have been
based on assessing predictive performance using pre-
defined sets of peptides, rather than well-defined stand-
ardized full-overlapping studies of complete antigens.
This introduces biases and the reported performances are
likely to be overestimates.
• HLA-II peptide binding is mediated through 9-mer
binding core, but longer peptides are used for experimen-
tal measurement of binding. Hereby we predict one ele-
ment (the 9-mer binding cores) and experimentally test
with another element (15-mer, or longer peptides). This
makes the improvement of false positive rate an impor-
tant issue in prediction of HLA-II binding and it requires
sophisticated statistical and machine learning approaches
(see [28,29,34]).
• Both ends of the peptide binding grooves in HLA-II mol-
ecules are open, allowing the peptides to be more variable
in length (typically 14–18 amino acids) and flanking res-
idues are known to selectively affect binding [9]. This
effect is not considered in most of the HLA-II prediction
methods.
• Some longer peptides bind MHC-II through multiple
overlapping 9-mer registers [34,35] adding further com-
plexity to the selection of actual binding cores. The sim-
pler question of identification of the location of 9-mer
binding is extended to identification of multiple binding
cores and their locations within the same peptide.
• Experimental measurements of HLA-II binding shows
variation depending on the conditions of the experiment,
even for the control peptides.
• Sufficient quantities of HLA-II binding data are available
only for some HLA-DR molecules while, notwithstanding
notable exceptions [35], HLA-DQ and -DP molecules
have been understudied.
• Presentation of HLA-II binding peptides depends on
antigen processing steps including editing by HLA-DM
and other accessory molecules. DM editing affects the
density and preference for particular peptide species [36].
These effects have not yet been included in the prediction
approaches.
HLA-II binding predictions are thus more complex than
HLA-I predictions [23,37,38]. Various prediction algo-
rithms have been developed to facilitate the identification
of HLA-II binding peptides within protein antigens. They
made computational pre-screening of antigens for HLA-II
epitopes a standard approach in epitope-mapping studies;
more than twenty prediction servers have been developed
to facilitate the identification of MHC-II binding peptides.
The performance of six prediction methods has been com-
pared in each of the three recent studies [28-30]. The over-
all conclusions of these studies were similar, indicating a
relatively low prediction accuracy of HLA-II binding pre-
dictors. Large quantities of HLA-DR binding peptides with
precise measurements have recently become available
[28,29], yet contemporary methods have shown little, if
any, improvement when compared to the older
TEPITOPE method.
This study extends the assessment of predictive power to
include a much larger number of servers that predict HLA-
II binding. This study was limited to seven common HLA-
DR molecules that have sufficient amount and quality of
peptide binding data. We compiled and established
standardized test data sets that are more representative of
the experimental reality, and defined a uniform scaling
scheme to use data from different studies. Finally we
assessed the practical applicability of HLA-II binding pre-
dictions to identification of HLA-II T-cell epitopes. Our
study identified several key issues that need to be
addressed for the development of improved prediction
systems of HLA-II binding.
Results
Classification
While not all the servers were designed specifically for
peptide binding predictions, all of them have imple-
mented modules for this step. Some servers also have
advanced options, for example, MHCPred enables users
to specify anchor positions. For this analysis we used thePage 3 of 10
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numbers of the servers for individual HLA-DR alleles we
studied were: HLA-DRB1*0101 – 19, HLA-DRB1*0301 –
15, HLA-DRB1*0401 – 20, HLA-DRB1*0701 – 16, HLA-
DRB1*1101 – 17, HLA-DRB1*1301 – 9, and HLA-
DRB1*1501 – 17.
In total 113 individual predictors were tested of which 17
showed good, 41 marginal, and 55 poor performance
using the single maximum 9-mer prediction scheme. 8
showed good, 30 marginal, and 75 poor performance
using the average prediction for all 9-mers within the test
peptide. Using the average of best of three 9-mer predic-
tions, 12 servers showed good, 37 marginal, and 64 poor,
performance. The AROC values of these predictions are
shown in Figure 1. An important finding from this analy-
sis is that overall, for the best prediction scheme (a single
best 9-mer), half of the prediction servers are not predic-
tive while only 15% of the servers show acceptable per-
formance. Other prediction schemes show even lower
predictive performance.
Comparing the prediction performance across HLA-DR
alleles, the best predictors are for HLA-DRB1*0101, where
seven predictors showed good classification accuracy,
while six DRB1*1101 predictors, three DRB1*0401 pre-
dictors, and only one DRB1*0701 predictor showed good
classification accuracy. None of predictors for
DRB1*0301, DRB1*1301, and DRB1*1501 showed good
classification performance. Important to note, only four
HLA-DRB1*0101 predictors have shown performance
that approaches the value of AROC = 0.9 while other
"good" predictors are close to the lower borderline leaving
ample space for the improvement.
The best prediction server across all HLA molecules evalu-
ated in this study is NETMHCIIPAN, closely followed by
PROPRED, IEDB_SAT, and MULTI_SVM. The best predic-
tors we recommend for each allele are marked by asterisks
in Figure 1.
Prediction of promiscuous peptides
Promiscuous peptides are able to bind to multiple MHC
molecules. Therefore they serve as promising targets for
vaccine design because they are likely to cover a larger
population of patients [39]. We performed analysis of pre-
diction of promiscuous peptides by assigning a score to
each peptide, which indicated the number of HLA-DR
molecules it binds to. The AROC was then calculated and
the results are shown in Figure 2. None of the predictors
showed good performance, while MHCPRED, RANKPEP,
PROPRED, IEDB_SAT, MULTI_HMM reached AROC values
higher than 0.775. DR4_ANN and DR4_SVM predictors
were excluded from this analysis since they predict pep-
tide binding to single MHC-II allele (HLA-DRB1*0401).
To enable the comparison of predictions that include
multiple HLA alleles, we developed a common scaling
scheme for seven HLA-DRB1 alleles.  Binding scores used
in this scheme range from 0 to 100 and threshold for
binding is at 50. The scaled data are accessible at DFRMLI
[42].
Prediction of T-cell epitopes
We also assessed the performance of prediction servers in
identification of tumor antigen T-cell epitopes. For each
server we predicted the binding affinity of all T-cell
epitopes and determined the thresholds at which approx-
imately 80% and 50% of tested T-cell epitopes were pre-
dicted as binders. The number of false positives (FPs) at
the thresholds was calculated for the four antigens and
representative results are shown in Table 1.
To identify 80% of T cell epitopes, the threshold for each
predictor had to be set low, which resulted in a large
number of false positives. This problem was pronounced
for predictors such as MHCPRED, MULTI_ANN and
RANKPEP, since the number of false positives even
exceeded that of true negatives. At this threshold, IEDB
(consensus), MULTPRED (SVM), and PROPRED showed
the best performance. On the other hand, the thresholds
for predicting ~50% of known T cell epitopes were much
more stringent, significantly lowering the rate of false pos-
itives relative to the 80% threshold. At this threshold, Net-
MHCIIpan, IEDB (consensus), and PROPRED showed the
best performance
Conclusion and discussion
In this study we evaluated the performance of 21 predic-
tion servers for HLA-II binding peptides. Seven
DRB1*0101 predictors, six DRB1*1101 predictors, three
DRB1*0401 predictors, and one DRB1*0701 predictor
showed good performance in identification of binders
and non-binders.  None of predictors for DRB1*0301,
DRB1*1301, and DRB1*1501 performed well, indicating
that much room for improvement still exists for MHC-II
prediction.
The results suggest that some of current predictors are use-
ful for pre-screening Th epitopes, although a relatively
large number of false positives (at lower thresholds) and
false negatives (at higher thresholds) would also be pro-
duced. Predictions using lower thresholds are useful for
screening true negatives, while predictions at higher
thresholds help cheaply identify a subset of the T-cell
epitopes. Unlike MHC-I predictions, we have no evidence
that nonlinear methods would perform better than linear
methods. One possible reason may be due to the fact that
nonlinear methods, such as ANN or SVM, generally
require relatively larger amount of data for model devel-
opment than linear methods. However, the amount ofPage 4 of 10
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AROC values of predictions by the 21 servers using the combined test set (103 peptides from the four antigens) based on the three mapping methods: black bars for maximum 9-mer scores, gr y bars for av rage cores of all overlappi g 9-m rs, and whit bars for th  average of the top three 9-mer scoresFigure 1
AROC values of predictions by the 21 servers using the combined test set (103 peptides from the four antigens) based on the 
three mapping methods: black bars for maximum 9-mer scores, grey bars for average scores of all overlapping 9-mers, and 
white bars for the average of the top three 9-mer scores. Vertical axis shows the AROC values while horizontal axis shows indi-
vidual servers, as designated in Table 2. Best performing predictors for each allele are marked by asterisks.
BMC Bioinformatics 2008, 9(Suppl 12):S22 http://www.biomedcentral.com/1471-2105/9/S12/S22high-quality binding data for MHC-II binding is still far
from sufficient, which limits the capability of nonlinear
methods to recognize characteristics underlying MHC-
peptide interaction
In summary, the prediction accuracy of HLA-II binding
peptides is inferior to that of HLA-I binding peptides. Sev-
eral factors appear to account for this disparity. Insuffi-
cient or low-quality training data has been the problem
for developers of prediction methods for HLA-II binding
peptides. Another problem with HLA-II predictions is the
difficulty in identifying 9-mer binding cores within longer
peptides used for training as well as lack of consideration
of the influence of flanking residues. Amino acids flank-
AROC values for prediction of promiscuous peptidesFigure 2
AROC values for prediction of promiscuous peptides. Vertical axis shows the AROC values while horizontal axis shows numbers 
designating individual servers, as shown in Table 2. The first two servers were excluded from the analysis because they pre-
dicted peptide binding to a single DR molecule.
Table 1: Prediction performance of selected representative servers at two scenarios: a) thresholds that correctly predict ~80% of T-cell 
epitopes; b) thresholds that correctly predict ~50% of T-cell epitopes.
Server Threshold TP FN TN FP TP (tumor epitopes)
a) 80% prediction
IEDB_ARB 100 10 5 56 32 17 (81%)
IEDB_ CON 11 10 5 70 18 17 (81%)
MHCPRED 15 10 5 36 52 17 (81%)
MULTI_ANN 3 15 0 38 50 17 (81%)
MULTI_SVM 6.4 13 2 59 29 17 (81%)
NETMHCII 4000 12 3 51 37 17 (81%)
NETMHCIIPAN 440 12 3 56 32 17 (81%)
PROPRED -1.5 14 1 54 34 17 (81%)
RANKPEP 0.85 12 3 41 47 17 (81%)
b) 50% prediction
IEDB_ARB 3 7 8 80 8 10 (48%)
IEDB_ CON 4 7 8 86 2 10 (48%)
MHCPRED 3 4 11 76 12 10 (48%)
MULTI_ANN 5 5 10 66 22 11 (52%)
MULTI_SVM 7.1 6 9 82 6 10 (48%)
NETMHCII 400 7 8 78 10 10 (48%)
NETMHCIIPAN 60 7 8 87 1 10 (48%)
PROPRED 0 10 5 81 7 11 (52%)
RANKPEP 7 10 5 69 19 11 (52%)Page 6 of 10
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tions and also antigen processing preferences [34,40].
Another reason of poor performance for MHC-II predic-
tion is that the binding groove of HLA-II molecules is rel-
atively permissive for peptide binding, which limits the
stringency of specific binding motifs. We propose that
with new large datasets available [29,37,41,42] new meth-
ods that implement knowledge-based strategies and com-
putational search techniques need to be developed.
Examples showing various approaches that can improve
HLA-binding prediction systems include the use of
advanced search algorithms [28,29,43], advanced statisti-
cal and machine learning approaches [44-47], combina-
tion approaches [28,38,48,49], novel scoring functions
[50], and improved use of structural predictions [51,52],
or application of knowledge-based approaches [53-57].
Future HLA-DR prediction developments studies should,
at minimum, use standardized data sets, provide
improved definition of binding cores, minimize number
of false positives, and consider the effects of flanking resi-
dues.
Results of this study will help researchers to determine the
most appropriate servers for pre-screening of HLA class II
binding peptides.  In addition, this study has defined
basic criteria for slection of predication thresholds for
selection of peptides that are most likely to be potential
HLA-II epitopes. On the other hand, it provides guidelines
for testing and test data to server developers. This knowl-
edge, together with standardized test data sets should
empower them to produce better solutions and improve
prediction performance. Normalization and standardiza-
tion methods that we introduced in this study enable
annotation and integration of heterogeneous data into a
uniform format, which facilitates the development of
advanced algorithms. Future advancement in high-
throughput measurements of binding affinities is
expected to significantly improve the prediction perform-
ance of MHC-II binding peptides.
Materials and methods
We evaluated 21 servers for prediction of HLA class II
binding peptides that have been developed by 12 groups
(Table 2). These servers were accessible over the Internet
as of July 2008. Predictive algorithms used in these servers
include: binding matrices, partial least square function,
artificial neural networks (ANN), hidden Markov models
(HMM), and support vector machines (SVM). Our study
involved five consecutive steps: a) Construct test data sets
by collecting independent experimental data; b) Retrieve
prediction results from the 21 servers; c) Assess the classi-
fication accuracy (binders vs. non-binders); d) Assess the
prediction accuracy of promiscuous binding affinities; e)
Assess the performance for predicting T cell epitopes.
Data sets
In this study our test data sets consisted of 103 peptides
derived from four protein antigens, including allergens –
bee venom phospholipase A2 (API m1) [58] and dog
lipocalin (Can f 1) [59], a tumor antigen LAGE-1 [60], and
a viral antigen HIV NEF [61]. Although these studies were
done by different groups, they were performed using com-
Table 2: List of prediction servers of HLA class II binding peptides, their URLs (as of December 2007), and name abbreviations.
ID Servers Abbreviation URLs Prediction algorithm Reference
1 HLA-DR4Pred (ANN) DR4_ANN [63] ANN [64]
2 HLA-DR4Pred (SVM) DR4_SVM [63] SVM [64]
3 IEDB (ARB) IEDB_II [65] Matrix [66]
4 IEDB (SMM) IEDB_SMM [65] Matrix [41]
5 IEDB (Saturniolo) IEDB_SAT [65] Matrix [67]
6 IEDB (Consensus) IEDB_CON [65] Matrix -
7 MHC Binder Prediction MHC_BP [68] Matrix -
8 MHC2Pred MHC2Pred [69] SVM -
9 MHC-BPS MHC_BPS [70] SVM [71]
10 MHCPred MHCPRED [72] Partial least square [73]
11 Multipred1 (ANN) MULTI_ANN [74] ANN [39]
12 Multipred1 (HMM) MULTI_HMM [74] HMM [39]
13 Multipred1 (SVM) MULTI_SVM [74] SVM [75]
14 NetMHCII NETMHCII [76] Matrix [41]
15 NetMHCIIpan NETMHCIIPAN [77] ANN [29]
16 PeptideCheck (Matrix) PEPC_M [78] Matrix [79]
17 ProPred PROPRED [80] Matrix [81]
18 Rankpep RANKPEP [82] Matrix [83]
19 SVMHC SVMHC [84] Matrix [85]
20 SVRMHC SVRMHC [86] SVM [87]
21 SYFPEITHI SYFPEITHI [88] Matrix [12]Page 7 of 10
(page number not for citation purposes)
BMC Bioinformatics 2008, 9(Suppl 12):S22 http://www.biomedcentral.com/1471-2105/9/S12/S22parable protocols and same control peptides. The lengths
of the studied peptides were in the range of 15 to 19
amino acids (Table 3). Binding capability of these pep-
tides to corresponding HLA molecules was measured by
the concentration of peptides that prevented binding of
50% of the labeled reference peptides. These studies
reported binding data for seven HLA-DR molecules
(DRB1*0101, 0301, 0401, 0701, 1101, 1301, and 1501).
The test data sets used in this study were extracted from
the original references and rescaled to a common scale.
The data used in this study are accessible at the Dana-Far-
ber Machine Learning Repository for Immunology
(DFRMLI) [42].
Predictions and comparisons
Each protein sequence was submitted to the prediction
servers and the results were recorded. Most servers predict
binding affinities of 9-mer peptides while the experiments
were conducted on longer peptides ranging from 15 aa to
19 aa. Three mapping methods were explored to map the
9-mer predictions to experimental results. First, the high-
est prediction score of the overlapping 9-mer peptides
spanning the length of a longer peptide was used as the
predicted binding of the longer peptide. Second, the aver-
age score of the overlapping 9-mers was used as the pre-
dicted binding. Finally, the average of the top three
predicted 9-mer scores of the overlapping peptides was
used as the prediction score.
Prediction accuracy is measured in terms of the area under
the receiver operating characteristic curve (AROC) [62]. The
ROC curve is a plot of the true positive rate TP/(TP+FN)
on the vertical axis vs. false positive rate FP/(TN+FP) on
the horizontal axis for the full range of the decision
thresholds. The values AROC ≥ 0.9 indicate excellent, 0.9 >
AROC ≥ 0.8 good, 0.8 > AROC ≥ 0.7 marginal and 0.7 > AROC
poor predictions [62].
In this study we defined promiscuous peptides as those
peptides from the test set that bound four or more of the
seven studied alleles. Binding was defined as half maximal
inhibitory concentration (IC50) lower than 100 nM (for
DRB1*0101, 0401, 0701, and 1501), or lower than 1000
nM (for DRB1*0301, 1101, and 1301).
Scaling
To enable visual inspection for comparisons of predic-
tions, both experimental measurements and predictions
have been scaled to a common scale from 0 to 100 by lin-
ear transformation of the value ranges using the formula
for each individual peptide:
where  is the scaled score, ymin is the minimum and ymax
is the maximum score. The experimental binding affinity
was corrected for variation in binding affinity of control
peptides between different experiments then scaled. All
values are accessible at DFRMLI site.
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